Eloxx gets Nasdaq extension to July 30, 2023 for continued listing; ELX-02 pivotal study planned

Eloxx Pharmaceuticals, Inc.

Nasdaq Hearings Panel granted extension through July 30, 2023 to regain compliance with $35M market value rule.
Extension is conditioned on achievement of certain milestones included in a compliance plan.
Company plans to advance ELX-02 into pivotal study in Alport Syndrome patients with nonsense mutations.
Plans depend on completing third patient dosing in Phase 2 trial, FDA discussions, and obtaining necessary capital.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.